GlassScriptPhysician profile
John Dipietra
NPI 1295770469
$2,111.11
in general payments reported to CMS, 2019-2025
27 companies · $818 in 2025
The $818 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.95 · 2020: $27.28 · 2021: $45.26 · 2022: $188 · 2023: $220 · 2024: $789 · 2025: $818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,827.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $327.13 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $275.90 | 2023-2025 | |
| Abbvie INC. | $242.29 | 2022-2025 | Ubrelvy |
| Glaxosmithkline, LLC. | $157.44 | 2022-2025 | Shingrix, Arexvy |
| Lilly USA, LLC | $146.45 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $140.34 | 2022-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $114.10 | 2024-2025 | Airsupra, Breztri, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $74.65 | 2024-2025 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.72 | 2024-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $70.38 | 2022 | |
| Abbott Laboratories | $68.91 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $68.41 | 2024-2025 | |
| Exact Sciences Corporation | $56.77 | 2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $36.00 | 2023-2024 | |
| Amgen INC. | $29.13 | 2025 | Evenity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $28.72 | 2021 | |
| Optinose US, INC. | $23.55 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $23.36 | 2024 | Crysvita |
| Xeris Pharmaceuticals, INC. | $22.84 | 2025 | Gvoke Hypopen |
| Procept Biorobotics Corporation | $21.16 | 2024 | Aquabeam System |
| Boston Scientific Corporation | $19.43 | 2025 | Watchman Access System |
| Dynavax Technologies Corporation | $17.96 | 2025 | Heplisav-B |
| Aimmune Therapeutics, INC. | $16.50 | 2025 | Zenpep |
| Alexion Pharmaceuticals, INC. | $15.34 | 2025 | Ultomiris |
| Dexcom, INC. | $14.78 | 2024 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $14.03 | 2025 | |
| Amneal Pharmaceuticals LLC | $13.82 | 2025 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dipietra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.